CDTX News and Press, Cidara Therapeutics Inc. From 07/27/22

Submitted NDA for rezafungin for candidemia and invasive candidiasis to the U.S. FDA on July 22, 2022, with an anticipated PDUFA target action date in the first quarter of 2023, if accepted for review following application validation Melinta acquires exclusive rights to commerci...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentat...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due t...

H.C. Wainwright Analyst Ed Arce lowered the price target on Cidara Therapeutics (NASDAQ:CDTX) to $6 from $7.50. The Buy rating on CDTX shares was kept. The biotechnology company had reported Q1 GAAP EPS of -$0.27 and revenue of $7.11M (+195.0% Y/Y). For further details see: H.C. Wa...

Cidara Therapeutics press release (NASDAQ:CDTX): Q1 GAAP EPS of -$0.27 beats by $0.01. Revenue of $7.11M (+195.0% Y/Y) beats by $2.4M. Shares +4.22%. For further details see: Cidara Therapeutics GAAP EPS of -$0.27 beats by $0.01, revenue of $7.11M beats by $2.4M

SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March...

SAN DIEGO and CAMBRIDGE, United Kingdom, April 14, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX) and Mundipharma today announced that the companies will present new clinical data and analyses of rezafungin, a novel, once-weekly echinocandin in development for the treatme...

Shares of Cidara Therapeutics Inc. (NASDAQ:CDTX) traded today at $15.92, eclipsing its 52-week high. This new high was reached on above average trading volume as 31.8 million shares traded hands, while the average 30-day volume is approximately 255,000 shares. Cidara Therapeutics Inc is ...

San Diego, California-based biotech, Cidara Therapeutics (NASDAQ:CDTX) is trading ~11% higher in the pre-market after announcing the completion of dosing in the first cohort of the Phase 1 trial for CD388, an immunotherapy candidate designed for the prevention of seasonal and pandemic in...

Cidara Therapeutics (NASDAQ:CDTX) dosed the first cohort of healthy volunteers in a phase 1 trial of its antiviral immunotherapy CD388 for preventing seasonal and pandemic influenza. The study is being conducted under an exclusive worldwide license and collaboration agreement with Johnso...